Juan Vasquez, MD
DownloadHi-Res Photo
Cards
Appointments
Titles
Associate Program Director, Pediatrics Hematology/Oncology Fellowship, Pediatrics
About
Titles
Assistant Professor of Pediatrics (Hematology/Oncology)
Associate Program Director, Pediatrics Hematology/Oncology Fellowship, PediatricsAppointments
Pediatric Hematology & Oncology
Assistant ProfessorPrimary
Other Departments & Organizations
- Cancer Immunology
- Human and Translational Immunology Program
- Janeway Society
- Molecular Medicine, Pharmacology, and Physiology
- Pediatric Hematology & Oncology
- Pediatric Hematology & Oncology Program
- Pediatrics
- Program in Translational Biomedicine (PTB)
- Yale Cancer Center
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Medicine
Education & Training
- Pediatric Hematology/Oncology Fellowship
- Yale School of Medicine (2016)
- MHS
- Yale School of Medicine (2016)
- Pediatric Residency
- Brown Medical School/Rhode Island Hospital (2013)
- MD
- Brown University (2010)
- BA
- Harvard University (2006)
Research
Overview
Medical Subject Headings (MeSH)
Brain Neoplasms; Immunotherapy; Sarcoma
ORCID
0000-0002-9031-7639
Research at a Glance
Yale Co-Authors
Frequent collaborators of Juan Vasquez's published research.
Publications Timeline
A big-picture view of Juan Vasquez's research output by year.
Research Interests
Research topics Juan Vasquez is interested in exploring.
Anita Huttner, MD
Asher Marks, MD
Ranjit S. Bindra, MD, PhD
Aladine Elsamadicy, MD
Farzana Pashankar, MD, MRCP, MBBS
W. Mark Saltzman, PhD
18Publications
353Citations
Brain Neoplasms
Publications
2024
NAPRT silencing in FH-deficient renal cell carcinoma confers therapeutic vulnerabilities via NAD+ depletion.
Noronha K, Lucas K, Paradkar S, Edmonds J, Friedman S, Murray M, Liu S, Sajed D, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram R, Shuch B, Vasquez J, Bindra R. NAPRT silencing in FH-deficient renal cell carcinoma confers therapeutic vulnerabilities via NAD+ depletion. Molecular Cancer Research 2024 PMID: 38949523, DOI: 10.1158/1541-7786.mcr-23-1003.Peer-Reviewed Original ResearchAltmetricConceptsRenal cell carcinomaCellular processesCell carcinomaFumarate hydrataseImpact diverse cellular processesAlpha-ketoglutarate-dependent dioxygenasesDiverse cellular processesAccumulation of fumaratePreiss-Handler pathwayMultiple cellular processesLoss of function mutationsAssociated with silencingNicotinamide phosphoribosyl transferase inhibitorPattern of hypermethylationFH-deficient renal cell carcinomasSynergistic tumor cell killingAggressive subtype of renal cell carcinomaLoss of FHSubtype of renal cell carcinomaDNA repair processesPoly(ADP)-ribose polymerase inhibitorsCpG islandsTumor cell killingPreiss-HandlerCell line modelsAntitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor
Malik S, Pradeep S, Kumar V, Xiao Y, Deng Y, Fan R, Vasquez J, Singh V, Bahal R. Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor. Cell Reports Medicine 2024, 5: 101354. PMID: 38183981, PMCID: PMC10829792, DOI: 10.1016/j.xcrm.2023.101354.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTarget genomic DNAGenomic DNASequencing of genomic DNAGenomic DNA levelInhibit c-myc transcriptionC-myc transcriptionGenomic DNA targetsTarget oncogenesMultiple cell linesC-Myc inhibitorCancer therapyHistone deacetylase inhibitorsRNA targetsDNA targetsPatient-derived xenograftsPre-clinical modelsDNADeacetylase inhibitorsCell linesOncogeneInhibiting oncogenesDNA levelsAntitumor efficacyPrecision medicineChemotherapeutic drugs
2023
MODL-02. DEVELOPMENT OF RODENT GLIOBLASTOMA MODELS OF MGMT-MEDIATED TEMOZOLOMIDE RESISTANCE
Lee T, Bhatt D, Sundaram R, Saltzman W, Bindra R, Vasquez J. MODL-02. DEVELOPMENT OF RODENT GLIOBLASTOMA MODELS OF MGMT-MEDIATED TEMOZOLOMIDE RESISTANCE. Neuro-Oncology 2023, 25: v298-v298. PMCID: PMC10640218, DOI: 10.1093/neuonc/noad179.1153.Peer-Reviewed Original ResearchConceptsMouse glioma modelPotential therapeutic targetMGMT overexpressionGlioma modelTherapeutic targetTumor growthDaily x 5 daysMGMT expressionMGMT inhibitorsUseful preclinical toolTumor immune microenvironmentImportant prognostic biomarkerFischer 344 ratsHuman GBM cell linesDelays tumor growthHigh MGMT expressionMouse glioma cellsRodent glioblastoma modelsSyngeneic Fischer 344 ratsGBM cell linesAlkylator therapyO6-methylguanine-DNA methyltransferaseChemoimmunotherapy combinationImmune microenvironmentSyngeneic modelUse of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors
Xu S, Campbell A, Chiang V, Bindra R, Vasquez J, Pashankar F. Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors. Pediatric Blood & Cancer 2023, 70: e30303. PMID: 36975152, DOI: 10.1002/pbc.30303.Peer-Reviewed Original ResearchAltmetricRhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Vasquez J, Luo L, Hiniker S, Rhee D, Dasgupta R, Chen S, Weigel B, Xue W, Venkatramani R, Arndt C. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatric Blood & Cancer 2023, 70: e30293. PMID: 36916768, PMCID: PMC10424503, DOI: 10.1002/pbc.30293.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEvent-free survivalMetastatic diseaseYears of ageOverall survivalOncology GroupLung metastasesExact testSoft Tissue Sarcoma CommitteeSuperior event-free survivalBetter survival outcomesKaplan-Meier methodChildren's Oncology GroupRisk stratification algorithmLog-rank testOutcome of childrenFisher's exact testN0 diseaseAggressive treatmentMetastatic rhabdomyosarcomaExtrapulmonary sitesMetastatic sitesExtremity tumorsSurvival outcomesEmbryonal histologyCOG protocols
2022
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors
Gueble SE, Vasquez JC, Bindra RS. The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. Current Treatment Options In Oncology 2022, 23: 1566-1589. PMID: 36242713, DOI: 10.1007/s11864-022-01024-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsMeSH Keywords and ConceptsConceptsHomologous recombination deficiencyPrimary CNS tumorsCNS tumorsClinical trialsPARP inhibitorsPreclinical evidencePrimary malignant central nervous system tumorMalignant central nervous system tumorsCentral nervous system tumorsImmune checkpoint inhibitorsStandard treatment modalityInitial clinical trialsEarly phase trialsNervous system tumorsCentral nervous tumorsExtracranial cancerCheckpoint inhibitorsDevastating malignancyStandard therapyOngoing trialsCombination therapyTreatment optionsTreatment modalitiesSystem tumorsPhase trialsMetastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide
Singh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide. Pediatric Blood & Cancer 2022, 70: e30020. PMID: 36151992, DOI: 10.1002/pbc.30020.Peer-Reviewed Original ResearchCitationsAltmetricTargeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy
Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. Oncotarget 2022, 13: 1054-1067. PMID: 36128328, PMCID: PMC9477221, DOI: 10.18632/oncotarget.28273.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdenosine Diphosphate RiboseAnimalsCarcinoma, Renal CellCitric Acid CycleDioxygenasesDNAFumarate HydrataseFumaratesHumansJumonji Domain-Containing Histone DemethylasesKidney NeoplasmsLysineMicePoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsSuccinate DehydrogenaseSuccinatesTemozolomideConceptsRenal cell carcinomaPoly ADP-ribose polymerase inhibitorsADP-ribose polymerase inhibitorsCell carcinomaSDH-deficient renal cell carcinomaPolymerase inhibitorsLow-dose temozolomideAggressive renal cell carcinomaHereditary cancer syndromesNovel therapeutic strategiesDeficient murine modelStandard dosingTMZ resultsMurine modelTherapeutic strategiesCombination treatmentCancer syndromesTumor growthHomologous recombination DNA repair pathwayAccumulation of fumarateHR deficiencyPARP inhibitionTemozolomideChemotherapyCarcinomaTOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular Cancer Therapeutics 2022, 21: 1090-1102. PMID: 35439320, PMCID: PMC9256811, DOI: 10.1158/1535-7163.mct-21-1000.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsATR inhibitorsTop1 inhibitorsHomologous recombination deficiencyNovel molecular interactionApoptotic cell deathCancer cellsTop1 cleavage complexesAtaxia telangiectasiaCleavage complexesCell deathDNA damageHigher DNA damageMolecular interactionsDNA baseKinase inhibitorsI inhibitorMolecular pharmacologyMouse xenograftsTOP1Recombination deficiencyTopoisomerase I inhibitorInhibitorsTumor growthRad3Predictive biomarkers
2021
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
Sule A, Van Doorn J, Sundaram RK, Ganesa S, Vasquez JC, Bindra RS. Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. NAR Cancer 2021, 3: zcab018. PMID: 34027408, PMCID: PMC8127964, DOI: 10.1093/narcan/zcab018.Peer-Reviewed Original ResearchCitationsAltmetric
Clinical Trials
Current Trials
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
HIC ID2000032978RoleSub InvestigatorPrimary Completion Date12/30/2026Recruiting ParticipantsA Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease
HIC ID2000032707RoleSub InvestigatorPrimary Completion Date08/01/2025Recruiting ParticipantsA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)
HIC ID2000032969RoleSub InvestigatorPrimary Completion Date07/05/2028Recruiting ParticipantsA Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
HIC ID2000028691RoleSub InvestigatorPrimary Completion Date05/01/2027Recruiting ParticipantsPrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
HIC ID2000026442RoleSub InvestigatorPrimary Completion Date11/30/2029Recruiting Participants
Academic Achievements and Community Involvement
activity Reviewer
Peer Review Groups and Grant Study SectionsSt. Baldrick'sDetails05/01/2016 - Presenthonor Hyundai Hope on Wheels Scholar Hope Grant
National AwardHyundai Hope on WheelsDetails07/01/2022United Stateshonor American Cancer Society-Yale Cancer Center Pilot Grant
Yale School of Medicine AwardYale Cancer CenterDetails06/01/2022United Stateshonor Castle Connolly Top Doctor
National AwardCastle ConnollyDetails05/23/2022United Stateshonor K08 Career Development Award
National AwardNIH/NCIDetails08/25/2021United States
Clinical Care
Overview
Clinical Specialties
Pediatric Hematology & Oncology
Fact Sheets
Rhabdomyosarcoma
Learn More on Yale MedicinePediatric Cancer Immunotherapy
Learn More on Yale MedicinePediatric Chemotherapy
Learn More on Yale MedicineAcute Lymphoblastic Leukemia (ALL)
Learn More on Yale Medicine
Board Certifications
Pediatric Hematology-Oncology
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 2017
Pediatrics
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 2013
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- May 02, 2024
56 Yale Pediatricians Recognized by Connecticut Magazine's 2024 “Top Doctors” List
- April 12, 2024
Yale Cancer Center Faculty and Trainees Present at AACR Annual Meeting
- January 05, 2024Source: SPR
The Society for Pediatric Research announces new members for 2024
- August 17, 2023
Rozalyn Levine Rodwin, MD, Awarded $100,000 Grant to Treat Survivors of Childhood Cancer
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.